Do analysts recommend BMGL or NIVF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BMGL or NIVF?

NewGenIvf Group has lower revenue, but higher earnings than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.10 -$9.50M N/A N/A NewGenIvf Group $4.73M 0.91 $9.88M N/A N/A

Is BMGL or NIVF more profitable?

Company Net Margins Return on Equity Return on Assets Basel Medical Group N/A N/A N/A NewGenIvf Group N/A N/A N/A

Does the media prefer BMGL or NIVF?

In the previous week, Basel Medical Group and Basel Medical Group both had 4 articles in the media. Basel Medical Group's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.50 indicating that Basel Medical Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Basel Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewGenIvf Group 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend BRTX or NIVF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BRTX or NIVF?

NewGenIvf Group has higher revenue and earnings than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biorestorative Therapies $360K 25.06 -$14.24M -$1.07 N/A NewGenIvf Group $4.73M 0.91 $9.88M N/A N/A

Do analysts rate NIVF or ADVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, NIVF or ADVB?

NewGenIvf Group has higher revenue and earnings than Advanced Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.91 $9.88M N/A N/A Advanced Biomed N/A N/A -$3.26M $4.82 1.12

Is NIVF or ADVB more profitable?

Advanced Biomed's return on equity of 87.74% beat NewGenIvf Group's return on equity. Company Net Margins Return on Equity Return on Assets NewGenIvf Group N/A N/A N/A Advanced Biomed N/A 87.74% 64.49%

Do analysts prefer ACON or NIVF?

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 161.32%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than NewGenIvf Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ACON or NIVF?

NewGenIvf Group has higher revenue and earnings than Aclarion. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 88.25 -$7.23M -$9.03 N/A NewGenIvf Group $4.73M 0.91 $9.88M N/A N/A

Does the media refer more to ACON or NIVF?

In the previous week, NewGenIvf Group had 3 more articles in the media than Aclarion. MarketBeat recorded 4 mentions for NewGenIvf Group and 1 mentions for Aclarion. Aclarion's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.50 indicating that Aclarion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewGenIvf Group 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend NIVF or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, NIVF or MGRX?

NewGenIvf Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.91 $9.88M N/A N/A Mangoceuticals $460K 13.62 -$20.64M -$1.49 N/A

Does the media prefer NIVF or MGRX?

In the previous week, NewGenIvf Group had 3 more articles in the media than Mangoceuticals. MarketBeat recorded 4 mentions for NewGenIvf Group and 1 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.05 beat NewGenIvf Group's score of -0.50 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Mangoceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NewGenIvf Group (NIVF) Competitors

$1.28 -0.05 (-3.83%)

As of 12:00 PM Eastern

Compare

NIVF vs. BMGL, BRTX, ADVB, ACON, and MGRX

Should you buy NewGenIvf Group stock or one of its competitors? MarketBeat compares NewGenIvf Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewGenIvf Group include Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), Advanced Biomed (ADVB), Aclarion (ACON), and Mangoceuticals (MGRX). These companies are all part of the "healthcare" industry.

How does NewGenIvf Group compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
NewGenIvf Group	N/A	N/A	N/A

66.2% of NewGenIvf Group shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Basel Medical Group and Basel Medical Group both had 4 articles in the media. Basel Medical Group's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.50 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Basel Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewGenIvf Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.10	-$9.50M	N/A	N/A
NewGenIvf Group	$4.73M	0.91	$9.88M	N/A	N/A

Basel Medical Group has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, NewGenIvf Group has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Summary

Basel Medical Group beats NewGenIvf Group on 4 of the 7 factors compared between the two stocks.

How does NewGenIvf Group compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

NewGenIvf Group has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. NewGenIvf Group's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
NewGenIvf Group	N/A	N/A	N/A

In the previous week, NewGenIvf Group had 4 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for NewGenIvf Group and 0 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.50 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
NewGenIvf Group	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has higher revenue and earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	25.06	-$14.24M	-$1.07	N/A
NewGenIvf Group	$4.73M	0.91	$9.88M	N/A	N/A

Biorestorative Therapies has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, NewGenIvf Group has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NewGenIvf Group beats Biorestorative Therapies on 7 of the 11 factors compared between the two stocks.

How does NewGenIvf Group compare to Advanced Biomed?

NewGenIvf Group (NASDAQ:NIVF) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.2% of NewGenIvf Group shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by company insiders. Comparatively, 27.0% of Advanced Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NewGenIvf Group has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Advanced Biomed's return on equity of 87.74% beat NewGenIvf Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Advanced Biomed	N/A	87.74%	64.49%

In the previous week, NewGenIvf Group had 4 more articles in the media than Advanced Biomed. MarketBeat recorded 4 mentions for NewGenIvf Group and 0 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.50 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
NewGenIvf Group	Negative
Advanced Biomed	Neutral

NewGenIvf Group has higher revenue and earnings than Advanced Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.91	$9.88M	N/A	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.12

Summary

NewGenIvf Group beats Advanced Biomed on 5 of the 9 factors compared between the two stocks.

How does NewGenIvf Group compare to Aclarion?

Aclarion (NASDAQ:ACON) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

7.5% of Aclarion shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, NewGenIvf Group had 3 more articles in the media than Aclarion. MarketBeat recorded 4 mentions for NewGenIvf Group and 1 mentions for Aclarion. Aclarion's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.50 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewGenIvf Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Aclarion has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, NewGenIvf Group has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

NewGenIvf Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. NewGenIvf Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
NewGenIvf Group	N/A	N/A	N/A

NewGenIvf Group has higher revenue and earnings than Aclarion.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	88.25	-$7.23M	-$9.03	N/A
NewGenIvf Group	$4.73M	0.91	$9.88M	N/A	N/A

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 161.32%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than NewGenIvf Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NewGenIvf Group beats Aclarion on 8 of the 14 factors compared between the two stocks.

How does NewGenIvf Group compare to Mangoceuticals?

NewGenIvf Group (NASDAQ:NIVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

NewGenIvf Group has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. NewGenIvf Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

NewGenIvf Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.91	$9.88M	N/A	N/A
Mangoceuticals	$460K	13.62	-$20.64M	-$1.49	N/A

In the previous week, NewGenIvf Group had 3 more articles in the media than Mangoceuticals. MarketBeat recorded 4 mentions for NewGenIvf Group and 1 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.05 beat NewGenIvf Group's score of -0.50 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Mangoceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewGenIvf Group beats Mangoceuticals on 8 of the 11 factors compared between the two stocks.

Get NewGenIvf Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NIVF vs. The Competition

Export

Metric	NewGenIvf Group	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.30M	$9.44B	$6.87B	$12.53B
Dividend Yield	N/A	1.60%	2.67%	7.39%
P/E Ratio	N/A	26.17	27.37	24.58
Price / Sales	0.91	18.49	497.51	81.40
Price / Cash	0.01	111.79	49.24	56.96
Price / Book	0.00	6.09	11.09	6.46
Net Income	$9.88M	$177.20M	$3.57B	$331.29M
7 Day Performance	-7.48%	-1.67%	0.08%	-0.69%
1 Month Performance	-13.35%	7.81%	5.37%	1.91%
1 Year Performance	-99.77%	11.77%	30.73%	22.26%

NewGenIvf Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NIVF NewGenIvf Group	2.522 of 5 stars	$1.28 -3.8%	N/A	-99.8%	$4.30M	$4.73M	N/A	N/A	Gap Down
BMGL Basel Medical Group	0.1754 of 5 stars	$6.21 +3.6%	N/A	-71.5%	$9.69M	$8.90M	N/A	36	Gap Up
BRTX Biorestorative Therapies	0.7121 of 5 stars	$0.35 -7.3%	N/A	-79.9%	$8.99M	$360K	N/A	7
ADVB Advanced Biomed	1.033 of 5 stars	$4.80 -10.3%	N/A	N/A	$7.92M	N/A	1.00	40	Gap Down
ACON Aclarion	3.1035 of 5 stars	$2.92 -2.5%	$7.50 +157.3%	-61.2%	$7.17M	$80K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NIVF) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewGenIvf Group (NIVF) Competitors

NIVF vs. BMGL, BRTX, ADVB, ACON, and MGRX

How does NewGenIvf Group compare to Basel Medical Group?

Summary

How does NewGenIvf Group compare to Biorestorative Therapies?

Summary

How does NewGenIvf Group compare to Advanced Biomed?

Summary

How does NewGenIvf Group compare to Aclarion?

Summary

How does NewGenIvf Group compare to Mangoceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIVF vs. The Competition

NewGenIvf Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewGenIvf Group (NIVF) Competitors

NIVF vs. BMGL, BRTX, ADVB, ACON, and MGRX

How does NewGenIvf Group compare to Basel Medical Group?

Is BMGL or NIVF more profitable?

Do insiders and institutionals believe in BMGL or NIVF?

Does the media prefer BMGL or NIVF?

Do analysts recommend BMGL or NIVF?

Which has higher valuation and earnings, BMGL or NIVF?

Which has more risk & volatility, BMGL or NIVF?

Summary

How does NewGenIvf Group compare to Biorestorative Therapies?

Is BRTX or NIVF more profitable?

Does the media prefer BRTX or NIVF?

Do analysts recommend BRTX or NIVF?

Which has preferable earnings & valuation, BRTX or NIVF?

Which has more risk and volatility, BRTX or NIVF?

Do institutionals & insiders believe in BRTX or NIVF?

Summary

How does NewGenIvf Group compare to Advanced Biomed?

Do analysts rate NIVF or ADVB?

Do institutionals & insiders hold more shares of NIVF or ADVB?

Which has more risk and volatility, NIVF or ADVB?

Is NIVF or ADVB more profitable?

Does the media prefer NIVF or ADVB?

Which has preferable valuation & earnings, NIVF or ADVB?

Summary

How does NewGenIvf Group compare to Aclarion?

Do insiders & institutionals believe in ACON or NIVF?

Does the media refer more to ACON or NIVF?

Which has more risk and volatility, ACON or NIVF?

Is ACON or NIVF more profitable?

Which has better valuation & earnings, ACON or NIVF?

Do analysts prefer ACON or NIVF?

Summary

How does NewGenIvf Group compare to Mangoceuticals?

Which has more risk & volatility, NIVF or MGRX?

Do insiders & institutionals hold more shares of NIVF or MGRX?

Do analysts recommend NIVF or MGRX?

Is NIVF or MGRX more profitable?

Which has preferable earnings and valuation, NIVF or MGRX?

Does the media prefer NIVF or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIVF vs. The Competition

NewGenIvf Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools